| Year |
Citation |
Score |
| 2024 |
Wang Y, Hu M, Finn OJ, Wang XS. Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion. Cancer Immunology Research. PMID 39137006 DOI: 10.1158/2326-6066.CIR-23-0932 |
0.357 |
|
| 2024 |
Zhang L, Strange M, Elishaev E, Zaidi S, Modugno F, Radolec M, Edwards RP, Finn OJ, Vlad AM. Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites. Frontiers in Immunology. 15: 1379175. PMID 39086481 DOI: 10.3389/fimmu.2024.1379175 |
0.674 |
|
| 2024 |
Yuan DY, McKeague ML, Raghu VK, Schoen RE, Finn OJ, Benos PV. Cellular and transcriptional profiles of peripheral blood mononuclear cells pre-vaccination predict immune response to preventative MUC1 vaccine. Biorxiv : the Preprint Server For Biology. PMID 38948837 DOI: 10.1101/2024.06.14.598031 |
0.358 |
|
| 2024 |
Cameron CM, Raghu V, Richardson B, Zagore LL, Tamilselvan B, Golden J, Cartwright M, Schoen RE, Finn OJ, Benos PV, Cameron MJ. Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention. Medrxiv : the Preprint Server For Health Sciences. PMID 38766010 DOI: 10.1101/2024.05.09.24305336 |
0.348 |
|
| 2024 |
Stanton SE, Castle PE, Finn OJ, Sei S, Emens LA. Advances and challenges in cancer immunoprevention and immune interception. Journal For Immunotherapy of Cancer. 12. PMID 38519057 DOI: 10.1136/jitc-2023-007815 |
0.305 |
|
| 2023 |
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, ... ... Finn OJ, et al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36892581 DOI: 10.1158/1078-0432.CCR-22-3168 |
0.756 |
|
| 2022 |
Çuburu N, Finn OJ, Van Der Burg SH. Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines. Frontiers in Immunology. 13: 924099. PMID 35686125 DOI: 10.3389/fimmu.2022.924099 |
0.304 |
|
| 2022 |
Jacqueline C, Dracz M, Xue J, Binder RJ, Minden J, Finn O. LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors. Oncoimmunology. 11: 2029083. PMID 35083098 DOI: 10.1080/2162402X.2022.2029083 |
0.352 |
|
| 2021 |
Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nature Reviews. Clinical Oncology. PMID 33976418 DOI: 10.1038/s41571-021-00508-x |
0.312 |
|
| 2020 |
Jacqueline C, Lee A, Frey N, Minden JS, Finn OJ. Inflammation-induced, abnormal expression of self-molecules on epithelial cells: targets for tumor immunoprevention. Cancer Immunology Research. PMID 32467324 DOI: 10.1158/2326-6066.Cir-19-0870 |
0.498 |
|
| 2020 |
Sivagnanalingam U, Beatty PL, Finn OJ. Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention. Molecular Carcinogenesis. PMID 32333615 DOI: 10.1002/Mc.23206 |
0.784 |
|
| 2020 |
Jacqueline C, Finn OJ. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. Seminars in Immunology. 47: 101394. PMID 32273212 DOI: 10.1016/J.Smim.2020.101394 |
0.469 |
|
| 2020 |
Finn OJ. Introduction to the special issue: Tumor antigens in the time of the coronavirus pandemic. Seminars in Immunology. 47: 101396. PMID 32253110 DOI: 10.1016/J.Smim.2020.101396 |
0.357 |
|
| 2020 |
Hashash JG, Beatty PL, Critelli K, Hartman DJ, Regueiro M, Tamim H, Regueiro MD, Binion DG, Finn OJ. Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn's Disease. Journal of Clinical Gastroenterology. PMID 32195770 DOI: 10.1097/Mcg.0000000000001340 |
0.748 |
|
| 2020 |
Finn OJ, Ochoa AC. Editorial: Myeloid Derived Suppressor Cells as Disease Modulators. Frontiers in Immunology. 11: 90. PMID 32082331 DOI: 10.3389/Fimmu.2020.00090 |
0.302 |
|
| 2020 |
Miller ML, Finn OJ. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods in Enzymology. 632: 431-456. PMID 32000909 DOI: 10.1016/Bs.Mie.2019.07.026 |
0.38 |
|
| 2019 |
Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronnello C, Hashash JG, Hartman DJ, Telmer CA, Miskov-Zivanov N, Finn OJ, Cascio S. Crosstalk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer. Cancer Immunology Research. PMID 31831633 DOI: 10.1158/2326-6066.Cir-19-0514 |
0.389 |
|
| 2019 |
Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Frontiers in Immunology. 10: 1401. PMID 31275327 DOI: 10.3389/Fimmu.2019.01401 |
0.81 |
|
| 2019 |
Finn OJ, Boardman L, Cruz-Correa M, Bansal A, Kastenberg D, Hurr C, Kaufman S, Akerley C, Dzubinski L, Felt A, Fursa K, Rodriguez LM, Richmond E, Umar A, Szabo E, et al. Abstract CT236: Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct236 |
0.428 |
|
| 2019 |
Finn OJ, Ward J, Krpata T, Bengtson L, McKolanis J, Kaufman S, Akerley C, Felt A, Fursa K, Holland A, Foster N, Salazar A, Wojtowicz M, Szabo E, Limburg P, et al. Abstract CT222: A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct222 |
0.419 |
|
| 2018 |
Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: Immune modulation taking the stage. Biochimica Et Biophysica Acta. PMID 29391185 DOI: 10.1016/J.Bbcan.2017.12.002 |
0.416 |
|
| 2018 |
Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 200: 385-391. PMID 29311379 DOI: 10.4049/Jimmunol.1701302 |
0.472 |
|
| 2018 |
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Beatty PL, Kastenberg D, Hur C, Dzubinski L, Rodriguez L, Salazar A, McKolanis J, Seisler D, Foster NR, Polley M, Limburg PJ, ... Finn OJ, et al. Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas Immunology. DOI: 10.1158/1538-7445.Am2018-Lb-305 |
0.745 |
|
| 2018 |
Miller ML, Lohmueller J, McKolanis JR, Schoen R, Finn OJ. Abstract 5643: TCRβ repertoire analysis from a prophylactic MUC1 cancer vaccine trial Cancer Research. 78: 5643-5643. DOI: 10.1158/1538-7445.Am2018-5643 |
0.484 |
|
| 2018 |
Schoen RE, Boardman LA, Cruz-Correa MR, Bansal A, Kastenberg DM, Hur C, Dzubinski L, Rodriguez L, Salazar A, McKolanis J, Beatty P, Pai R, Seisler D, Foster NR, Polley M, ... ... Finn OJ, et al. Mo1987 - Randomized, Double-Blind, Placebo-Controlled Immunoprevention Trial with MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas Gastroenterology. 154: S-873. DOI: 10.1016/S0016-5085(18)32950-0 |
0.745 |
|
| 2017 |
Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 7: e1368604. PMID 29296519 DOI: 10.1080/2162402X.2017.1368604 |
0.437 |
|
| 2017 |
Cascio S, Faylo JL, Sciurba JC, Xue J, Ranganathan S, Lohmueller JJ, Beatty PL, Finn OJ. Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer. Oncotarget. 8: 105284-105298. PMID 29285251 DOI: 10.18632/Oncotarget.22168 |
0.75 |
|
| 2017 |
Finn OJ. The dawn of vaccines for cancer prevention. Nature Reviews. Immunology. PMID 29279613 DOI: 10.1038/Nri.2017.140 |
0.493 |
|
| 2017 |
Finn OJ, Rammensee HG. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. Cold Spring Harbor Perspectives in Biology. PMID 29254980 DOI: 10.1101/Cshperspect.A028829 |
0.418 |
|
| 2017 |
Finn OJ. Human Tumor Antigens Yesterday, Today, and Tomorrow. Cancer Immunology Research. 5: 347-354. PMID 28465452 DOI: 10.1158/2326-6066.Cir-17-0112 |
0.475 |
|
| 2017 |
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 77: 1510-1541. PMID 28373404 DOI: 10.1158/0008-5472.Can-16-2346 |
0.424 |
|
| 2017 |
Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacology & Therapeutics. PMID 28322974 DOI: 10.1016/J.Pharmthera.2017.03.008 |
0.458 |
|
| 2017 |
Cascio S, Faylo J, Sriram R, Vlad A, Camacho C, Finn OJ. Abstract 4126: Validation of hypoglycosylated MUC1-CIN85 protein-protein interaction as a new therapeutic target for prevention of cancer invasion and metastasis Cancer Research. 77: 4126-4126. DOI: 10.1158/1538-7445.Am2017-4126 |
0.693 |
|
| 2017 |
Lohmueller JJ, Ham JD, Finn OJ. Abstract 3747: msa2 biotin-binding CAR combined with biotinylated tumor-specific antibodies or DNA aptamers for universal cancer immunotherapy Immunology. 77: 3747-3747. DOI: 10.1158/1538-7445.Am2017-3747 |
0.355 |
|
| 2017 |
Hashash JG, Beatty P, Critelli K, Regueiro M, Hartman DJ, Regueiro MD, Binion DG, Goldby-Reffner K, Finn OJ. Overexpression and Hypoglycosylation of MUC1 is Associated with Endoscopic Recurrence of Post-Operative Crohn’s Disease Gastroenterology. 152: S210. DOI: 10.1016/S0016-5085(17)31006-5 |
0.725 |
|
| 2016 |
Cascio S, Finn OJ. Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis. Biomolecules. 6. PMID 27754373 DOI: 10.3390/biom6040039 |
0.348 |
|
| 2016 |
Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee S, Dekaban GA, Fink C, Foster P, et al. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer. Cancer Immunology Research. PMID 27604597 DOI: 10.1158/2326-6066.Cir-15-0189 |
0.477 |
|
| 2016 |
Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Scientific Reports. 6: 31740. PMID 27545199 DOI: 10.1038/Srep31740 |
0.486 |
|
| 2016 |
Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunology, Immunotherapy : Cii. PMID 27106024 DOI: 10.1007/S00262-016-1838-1 |
0.804 |
|
| 2016 |
Finn OJ, Beatty PL. Cancer immunoprevention. Current Opinion in Immunology. 39: 52-8. PMID 26799207 DOI: 10.1016/j.coi.2016.01.002 |
0.772 |
|
| 2016 |
Hashash JG, Beatty P, Regueiro M, Hartman DJ, Binion DG, Landau M, Finn OJ. Abnormal MUC1 Expression in Post-operative Crohnʼs Disease Recurrence American Journal of Gastroenterology. 111: S306-S307. DOI: 10.14309/00000434-201610001-00673 |
0.729 |
|
| 2016 |
Cascio S, Faylo J, Xue J, Finn O. Abstract 4153: Abnormal expression of MUC1 mucin on colon epithelia stimulates production of pro-inflammatory cytokines promoting colitis-associated colon cancer in a murine model Cancer Research. 76: 4153-4153. DOI: 10.1158/1538-7445.Am2016-4153 |
0.416 |
|
| 2015 |
Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A. Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study. Disease Markers. 2015: 179689. PMID 26693201 DOI: 10.1155/2015/179689 |
0.353 |
|
| 2015 |
Finn OJ, Khleif SN, Herberman RB. The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them. Cancer Prevention Research (Philadelphia, Pa.). 8: 1011-6. PMID 26353948 DOI: 10.1158/1940-6207.Capr-15-0234 |
0.432 |
|
| 2015 |
Cascio S, Finn OJ. Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis. Cancers. 7: 342-52. PMID 25675408 DOI: 10.3390/Cancers7010342 |
0.435 |
|
| 2015 |
Finn O, Schoen R, McKolanis J, Steele C, Stafova P, Richards S, Quintero A, Cameron M. Abstract PR02: MUC1 vaccine for colon cancer prevention: Microarray and bioinformatic analysis of pre-vaccination gene signatures distinguishing responders from non-responders Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Pr02 |
0.481 |
|
| 2015 |
Cascio S, Sciurba J, Finn O. Abstract 2886: Epigenetic regulation of MUC1 in NF-kB target gene expression of pro-inflammatory cytokines in colon cancer Cancer Research. 75: 2886-2886. DOI: 10.1158/1538-7445.Am2015-2886 |
0.409 |
|
| 2015 |
Lohmueller JJ, Sato S, Cheung WC, Chu I, Popova L, Manning CA, Crosby K, Grange C, Ham JD, Polakiewicz RD, Finn OJ. Abstract 2509: Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies Immunology. 75: 2509-2509. DOI: 10.1158/1538-7445.Am2015-2509 |
0.437 |
|
| 2014 |
Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunology Research. 2: 708-13. PMID 25092812 DOI: 10.1158/2326-6066.Cir-14-0110 |
0.507 |
|
| 2014 |
Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunology Research. 2: 263-73. PMID 24778322 DOI: 10.1158/2326-6066.Cir-13-0125 |
0.804 |
|
| 2014 |
Marvel DM, Finn OJ. Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10. Frontiers in Immunology. 5: 59. PMID 24596571 DOI: 10.3389/Fimmu.2014.00059 |
0.806 |
|
| 2014 |
Farkas AM, Finn OJ. Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. Journal of Immunology (Baltimore, Md. : 1950). 192: 658-65. PMID 24337381 DOI: 10.4049/Jimmunol.1301904 |
0.755 |
|
| 2014 |
Cascio S, Sciurba J, Hughey R, Camacho C, Finn O. Abstract 3151: Muc1/Cin85 complex is a new molecular target for control of cancer invasion and metastasis Cancer Research. 74: 3151-3151. DOI: 10.1158/1538-7445.Am2014-3151 |
0.423 |
|
| 2013 |
Mandapathil M, Visus C, Finn OJ, Lang S, Whiteside TL. Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology. 2: e25514. PMID 24073385 DOI: 10.4161/Onci.25514 |
0.387 |
|
| 2013 |
Cascio S, Farkas AM, Hughey RP, Finn OJ. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration Oncotarget. 4: 1686-1697. PMID 24072600 DOI: 10.18632/Oncotarget.1265 |
0.75 |
|
| 2013 |
Reichenbach DK, Finn OJ. Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2: e23429. PMID 23802084 DOI: 10.4161/Onci.23429 |
0.436 |
|
| 2013 |
Finn OJ, Schuler G. Introduction to The Renaissance of Cancer Immunotherapy. Annals of the New York Academy of Sciences. 1284: v-vii. PMID 23651200 DOI: 10.1111/Nyas.12153 |
0.359 |
|
| 2013 |
Beatty PL, Finn OJ. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Annals of the New York Academy of Sciences. 1284: 52-6. PMID 23651193 DOI: 10.1111/Nyas.12108 |
0.81 |
|
| 2013 |
Farkas AM, Marvel DM, Finn OJ. Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. Journal of Immunology (Baltimore, Md. : 1950). 190: 3319-27. PMID 23420890 DOI: 10.4049/Jimmunol.1203321 |
0.799 |
|
| 2013 |
Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prevention Research (Philadelphia, Pa.). 6: 18-26. PMID 23248097 DOI: 10.1158/1940-6207.Capr-12-0275 |
0.478 |
|
| 2013 |
Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opinion On Biological Therapy. 13: 35-49. PMID 22998452 DOI: 10.1517/14712598.2012.725719 |
0.494 |
|
| 2013 |
Zhang L, Vlad A, Milcarek C, Finn OJ. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunology, Immunotherapy : Cii. 62: 423-35. PMID 22941036 DOI: 10.1007/S00262-012-1325-2 |
0.657 |
|
| 2013 |
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. viii6-9. PMID 22918931 DOI: 10.1093/annonc/mds256 |
0.346 |
|
| 2013 |
Gao X, Li G, Teng B, Yang Q, Zhu Y, Zhang X, Finn OJ, Lu B. Abstract A66: IL-33 promotes CD8 T cell effector function and has a potent antitumor activity in vivo. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A66 |
0.397 |
|
| 2012 |
Finn OJ. Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. Experimental and Molecular Pathology. 93: 315-8. PMID 23099314 DOI: 10.1016/J.Yexmp.2012.10.013 |
0.418 |
|
| 2012 |
Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: S1-100. PMID 22977188 DOI: 10.1158/1078-0432.Ccr-12-2891 |
0.339 |
|
| 2012 |
Beatty P, Ranganathan S, Finn OJ. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology. 1: 263-270. PMID 22737601 DOI: 10.4161/Onci.18950 |
0.791 |
|
| 2012 |
Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA. Preventive immunization of aged and juvenile non-human primates to β-amyloid. Journal of Neuroinflammation. 9: 84. PMID 22554253 DOI: 10.1186/1742-2094-9-84 |
0.376 |
|
| 2012 |
Kimura T, McKolanis JR, Schoen RE, Finn OJ. Abstract 5380: Prophylactic MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma Cancer Research. 72: 5380-5380. DOI: 10.1158/1538-7445.Am2012-5380 |
0.479 |
|
| 2012 |
Cascio S, Finn O. Abstract 492: Identification of a novel complex MUC1/CIN85 involved in invasion and migration of breast cancer cells Cancer Research. 72: 492-492. DOI: 10.1158/1538-7445.Am2012-492 |
0.404 |
|
| 2011 |
Patel AK, Appleman LJ, Gooding WE, Friedland D, McKolanis J, Salazar AM, Finn OJ, Chatta GS. A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2564. PMID 28022298 DOI: 10.1200/Jco.2011.29.15_Suppl.2564 |
0.4 |
|
| 2011 |
Cascio S, Zhang L, Finn OJ. MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. The Journal of Biological Chemistry. 286: 42248-56. PMID 22021035 DOI: 10.1074/Jbc.M111.297630 |
0.419 |
|
| 2011 |
Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunologic Research. 50: 261-8. PMID 21717081 DOI: 10.1007/S12026-011-8214-1 |
0.769 |
|
| 2011 |
Finn OJ. Abstract CN08-04: Testing cancer vaccines in the setting of premalignant disease: State of immunity and determinants of response Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-Cn08-04 |
0.534 |
|
| 2011 |
Kimura T, McKolanis JR, Schoen RE, Finn OJ. Abstract 5510: Immunogenicity of the MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma Cancer Research. 71: 5510-5510. DOI: 10.1158/1538-7445.Am2011-5510 |
0.488 |
|
| 2010 |
Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology, Immunotherapy : Cii. 59: 1685-96. PMID 20652244 DOI: 10.1007/S00262-010-0895-0 |
0.451 |
|
| 2010 |
Ryan SO, Turner MS, Gariépy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Research. 70: 5788-96. PMID 20587526 DOI: 10.1158/0008-5472.CAN-09-4519 |
0.356 |
|
| 2010 |
Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF, Finn OJ. Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes & Control : Ccc. 21: 1193-201. PMID 20559706 DOI: 10.1007/S10552-010-9546-1 |
0.402 |
|
| 2010 |
Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1595-601. PMID 20501761 DOI: 10.1158/1055-9965.Epi-10-0068 |
0.347 |
|
| 2010 |
Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Seminars in Immunology. 22: 125-31. PMID 20403708 DOI: 10.1016/J.Smim.2010.03.003 |
0.781 |
|
| 2010 |
Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer Cancer Prevention Research. 3: 438-446. PMID 20332301 DOI: 10.1158/1940-6207.Capr-09-0194 |
0.815 |
|
| 2010 |
Guinipero T, Finn OJ. Cancer vaccines: emphasis on pediatric cancers. Current Pharmaceutical Design. 16: 292-9. PMID 20109138 |
0.34 |
|
| 2010 |
Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas. 39: 510-5. PMID 20084048 DOI: 10.1097/Mpa.0B013E3181Bd6501 |
0.74 |
|
| 2010 |
Furr AE, Ranganathan S, Finn OJ. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 13: 24-31. PMID 19025220 DOI: 10.2350/08-06-0479.1 |
0.385 |
|
| 2009 |
Finn OJ, Edwards RP. Human papillomavirus vaccine for cancer prevention. The New England Journal of Medicine. 361: 1899-901. PMID 19890134 DOI: 10.1056/Nejme0907480 |
0.388 |
|
| 2009 |
Vella LA, Yu M, Phillips AB, Finn OJ. Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Annals of the New York Academy of Sciences. 1174: 68-73. PMID 19769738 DOI: 10.1111/J.1749-6632.2009.04941.X |
0.403 |
|
| 2009 |
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.Ccr-09-0737 |
0.457 |
|
| 2009 |
Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 14010-5. PMID 19666607 DOI: 10.1073/Pnas.0903225106 |
0.471 |
|
| 2009 |
Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice Biological Chemistry. 390: 611-618. PMID 19426130 DOI: 10.1515/Bc.2009.070 |
0.699 |
|
| 2009 |
Silk AW, Schoen RE, Potter DM, Finn OJ. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Molecular Immunology. 47: 52-6. PMID 19217667 DOI: 10.1016/J.Molimm.2008.12.025 |
0.351 |
|
| 2009 |
Chen X, Gao W, Gambotto A, Finn OJ. Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 977-87. PMID 19023569 DOI: 10.1007/S00262-008-0624-0 |
0.398 |
|
| 2009 |
Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Molecular Immunology. 47: 131-40. PMID 19007994 DOI: 10.1016/J.Molimm.2008.09.032 |
0.402 |
|
| 2009 |
Turner M, Finn O, Morel P. T.31. Antigen Dose Over-rides DC Phenotype in the Control of CD4+Regulatory T Cell Induction Clinical Immunology. 131: S60. DOI: 10.1016/J.Clim.2009.03.172 |
0.33 |
|
| 2008 |
Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy. 6: 955-964. PMID 19129927 |
0.386 |
|
| 2008 |
Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Critical Reviews in Oncology/Hematology. 67: 93-102. PMID 18400507 DOI: 10.1016/J.Critrevonc.2008.02.010 |
0.408 |
|
| 2008 |
Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Research. 68: 2419-26. PMID 18381450 DOI: 10.1158/0008-5472.Can-07-2249 |
0.445 |
|
| 2008 |
Finn OJ. Tumor immunology top 10 list. Immunological Reviews. 222: 5-8. PMID 18363991 DOI: 10.1111/J.1600-065X.2008.00623.X |
0.333 |
|
| 2008 |
Beatty P, Kadayakkara D, Turner M, Janjic J, Ahrens E, Finn O. Overexpression of abnormal epithelial glycoprotein MUC1 is associated with pancreatitis and other extraintestinal complications in inflammatory bowel disease (IBD) The Faseb Journal. 22: 450-450. DOI: 10.1096/Fasebj.22.2_Supplement.450 |
0.733 |
|
| 2008 |
Carlos CA, Finn OJ. Dendritic Cells in Human Cancer Handbook of Dendritic Cells. 3: 1081-1092. DOI: 10.1002/9783527619696.ch51 |
0.772 |
|
| 2007 |
Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death and Differentiation. 15: 70-9. PMID 18007660 DOI: 10.1038/sj.cdd.4402274 |
0.327 |
|
| 2007 |
Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. Journal of Immunology (Baltimore, Md. : 1950). 179: 735-9. PMID 17617560 DOI: 10.4049/Jimmunol.179.2.735 |
0.771 |
|
| 2007 |
Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncology (London, England). 3: 299-306. PMID 17547525 DOI: 10.2217/14796694.3.3.299 |
0.453 |
|
| 2007 |
Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. Journal of Immunology (Baltimore, Md. : 1950). 178: 2787-93. PMID 17312122 DOI: 10.4049/Jimmunol.178.5.2787 |
0.481 |
|
| 2007 |
Finn OJ. Human tumor immunology at the molecular divide. Journal of Immunology (Baltimore, Md. : 1950). 178: 2615-6. PMID 17312098 DOI: 10.4049/Jimmunol.178.5.2615 |
0.343 |
|
| 2007 |
Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 30-5. PMID 17220329 DOI: 10.1158/1055-9965.Epi-06-0688 |
0.366 |
|
| 2007 |
Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. International Archives of Allergy and Immunology. 142: 179-89. PMID 17106205 DOI: 10.1159/000097020 |
0.431 |
|
| 2007 |
Geller BA, Lepisto AJ, Ahrendt GM, Finn OJ, Ramanathan RK, Brufsky AM. Immunity to MUC1 in pancreatic and breast cancer Journal of Clinical Oncology. 25: 21166-21166. DOI: 10.1200/Jco.2007.25.18_Suppl.21166 |
0.469 |
|
| 2006 |
Finn OJ. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunologic Research. 36: 73-82. PMID 17337768 DOI: 10.1385/Ir:36:1:73 |
0.5 |
|
| 2006 |
Vella LA, Finn OJ. Innate and adaptive immunity in lung cancer. Novartis Foundation Symposium. 279: 206-12; discussion 2. PMID 17278396 DOI: 10.1002/9780470035399.Ch16 |
0.379 |
|
| 2006 |
Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J, Palucka AK. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Research : Bcr. 8: R65. PMID 17129372 DOI: 10.1186/Bcr1621 |
0.445 |
|
| 2006 |
Alajez NM, Eghtesad S, Finn OJ. Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. Journal of Biomedicine & Biotechnology. 2006: 68091. PMID 16883054 DOI: 10.1155/Jbb/2006/68091 |
0.327 |
|
| 2006 |
Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Research. 66: 6-9. PMID 16397206 DOI: 10.1158/0008-5472.Can-05-3389 |
0.449 |
|
| 2006 |
Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunology, Immunotherapy : Cii. 55: 119-30. PMID 16032397 DOI: 10.1007/S00262-005-0008-7 |
0.37 |
|
| 2005 |
Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Annals of the New York Academy of Sciences. 1062: 29-40. PMID 16461786 DOI: 10.1196/Annals.1358.005 |
0.372 |
|
| 2005 |
Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treatment and Research. 123: 89-111. PMID 16211867 DOI: 10.1007/0-387-27545-2_4 |
0.384 |
|
| 2005 |
Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. Journal of Immunology (Baltimore, Md. : 1950). 175: 1628-35. PMID 16034102 DOI: 10.4049/Jimmunol.175.3.1628 |
0.795 |
|
| 2005 |
Oppenheim JJ, Dong HF, Plotz P, Caspi RR, Dykstra M, Pierce S, Martin R, Carlos C, Finn O, Koul O, Howard OM. Autoantigens act as tissue-specific chemoattractants. Journal of Leukocyte Biology. 77: 854-61. PMID 15917448 DOI: 10.1189/Jlb.1004623 |
0.79 |
|
| 2005 |
Alajez NM, Schmielau J, Alter MD, Cascio M, Finn OJ. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 105: 4583-9. PMID 15746083 DOI: 10.1182/Blood-2004-10-3848 |
0.458 |
|
| 2005 |
Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1521-6. PMID 15746055 DOI: 10.1158/1078-0432.Ccr-04-0538 |
0.464 |
|
| 2005 |
Finn OJ. Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004. Cancer Immunology, Immunotherapy : Cii. 54: 287-9. PMID 15517257 DOI: 10.1007/S00262-004-0618-5 |
0.353 |
|
| 2005 |
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 54: 254-64. PMID 15372205 DOI: 10.1007/S00262-004-0581-1 |
0.427 |
|
| 2004 |
Finn OJ, Whiteside T, McKolanis J, Moser AJ, Zeh H, Lee K, Bartlett D, Schmotzer A, Ramanathan RK. A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2578. PMID 28015290 DOI: 10.1200/Jco.2004.22.90140.2578 |
0.457 |
|
| 2004 |
Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Disease. 20: 73-9. PMID 15687709 DOI: 10.3233/Bd-2004-20109 |
0.721 |
|
| 2004 |
Finn OJ. Tumor immunology at the service of cancer immunotherapy. Current Opinion in Immunology. 16: 127-9. PMID 15023402 DOI: 10.1016/J.Coi.2004.02.006 |
0.364 |
|
| 2004 |
Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Advances in Immunology. 82: 249-93. PMID 14975259 DOI: 10.1016/S0065-2776(04)82006-6 |
0.706 |
|
| 2004 |
Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. European Journal of Immunology. 33: 3242-54. PMID 14635032 DOI: 10.1002/Eji.200324189 |
0.335 |
|
| 2003 |
Turner MS, McKolanis JR, Ramanathan RK, Whitcomb DC, Finn OJ. Mucins in gastrointestinal cancers. Cancer Chemotherapy and Biological Response Modifiers. 21: 259-74. PMID 15338749 DOI: 10.1016/S0921-4410(03)21012-7 |
0.357 |
|
| 2003 |
Finn OJ. Premalignant lesions as targets for cancer vaccines. The Journal of Experimental Medicine. 198: 1623-6. PMID 14638849 DOI: 10.1084/Jem.20031787 |
0.348 |
|
| 2003 |
Finn OJ. Cancer vaccines: between the idea and the reality. Nature Reviews. Immunology. 3: 630-41. PMID 12974478 DOI: 10.1038/Nri1150 |
0.452 |
|
| 2003 |
Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology. 108: 32-41. PMID 12519300 DOI: 10.1046/J.1365-2567.2003.01562.X |
0.675 |
|
| 2003 |
Suzuki H, Graziano D, McKolanis J, Min Y, Finn OJ. P-491 Immune response against cyclin B1 as a tumor antigen in patients with lung cancer and benign lung disease Lung Cancer. 41: S214-S215. DOI: 10.1016/S0169-5002(03)92458-5 |
0.376 |
|
| 2002 |
Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Hanisch FG, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. The Journal of Experimental Medicine. 196: 1435-46. PMID 12461079 DOI: 10.1084/Jem.20020493 |
0.692 |
|
| 2002 |
Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clinical & Experimental Metastasis. 19: 339-45. PMID 12090474 DOI: 10.1023/A:1015590515957 |
0.4 |
|
| 2002 |
Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Molecular Immunology. 38: 981-7. PMID 12009577 DOI: 10.1016/S0161-5890(02)00026-3 |
0.394 |
|
| 2002 |
Finn OJ, Forni G. Prophylactic cancer vaccines. Current Opinion in Immunology. 14: 172-7. PMID 11869888 DOI: 10.1016/S0952-7915(02)00317-5 |
0.459 |
|
| 2001 |
Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. The Journal of Experimental Medicine. 194: 1313-23. PMID 11696596 DOI: 10.1084/Jem.194.9.1313 |
0.761 |
|
| 2001 |
Soares M, Hanisch FG, Finn OJ, Ciborowski P. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity. Protein Expression and Purification. 22: 92-100. PMID 11388805 DOI: 10.1006/Prep.2001.1414 |
0.461 |
|
| 2001 |
Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of Immunology (Baltimore, Md. : 1950). 166: 6555-63. PMID 11359807 DOI: 10.4049/Jimmunol.166.11.6555 |
0.48 |
|
| 2001 |
Kao H, Amoscato AA, Ciborowski P, Finn OJ. A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 773s-780s. PMID 11300472 |
0.758 |
|
| 2000 |
Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 3730-41. PMID 11034378 DOI: 10.4049/Jimmunol.165.7.3730 |
0.7 |
|
| 2000 |
Ciborowski P, Finn OJ. Expression of MUC1 in insect cells using recombinant baculovirus. Methods in Molecular Biology (Clifton, N.J.). 125: 471-86. PMID 10820783 DOI: 10.1385/1-59259-048-9:471 |
0.33 |
|
| 1999 |
Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cellular Immunology. 194: 143-9. PMID 10383817 DOI: 10.1006/Cimm.1999.1512 |
0.384 |
|
| 1998 |
Henderson RA, Konitsky WM, Barratt-Boyes SM, Soares M, Robbins PD, Finn OJ. Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 247-56. PMID 9672846 DOI: 10.1097/00002371-199807000-00002 |
0.465 |
|
| 1998 |
Kirii Y, Magarian-Blander J, Alter MD, Kotera Y, Finn OJ. Functional and molecular analysis of T cell receptors used by pancreatic- and breast tumor- (mucin-) specific cytotoxic T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 188-97. PMID 9610910 DOI: 10.1097/00002371-199805000-00004 |
0.313 |
|
| 1998 |
Barratt-Boyes SM, Kao H, Finn OJ. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 142-8. PMID 9551366 DOI: 10.1097/00002371-199803000-00008 |
0.779 |
|
| 1998 |
Finn OJ, Lotze MT. Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Journal of Immunotherapy. 21: 114-118. PMID 9551362 DOI: 10.1097/00002371-199803000-00004 |
0.38 |
|
| 1998 |
Ciborowski P, Konitzki WM, Blander JM, Finn OJ. Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 19: 147-51. PMID 9422100 DOI: 10.1159/000056516 |
0.365 |
|
| 1997 |
Arcasoy SM, Latoche J, Gondor M, Watkins SC, Henderson RA, Hughey R, Finn OJ, Pilewski JM. MUC1 and other sialoglycoconjugates inhibit adenovirus-mediated gene transfer to epithelial cells. American Journal of Respiratory Cell and Molecular Biology. 17: 422-35. PMID 9376117 DOI: 10.1165/Ajrcmb.17.4.2714 |
0.3 |
|
| 1997 |
Barratt-Boyes SM, Watkins SC, Finn OJ. Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. Advances in Experimental Medicine and Biology. 417: 71-5. PMID 9286340 DOI: 10.1007/978-1-4757-9966-8_12 |
0.363 |
|
| 1997 |
Taylor-Papadimitriou J, Finn OJ. Biology, biochemistry and immunology of carcinoma-associated mucins. Immunology Today. 18: 105-7. PMID 9078680 DOI: 10.1016/S0167-5699(97)01028-1 |
0.304 |
|
| 1997 |
Poland PA, Kinlough CL, Rokaw MD, Magarian-Blander J, Finn OJ, Hughey RP. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines Glycoconjugate Journal. 14: 89-96. PMID 9076518 DOI: 10.1023/A:1018569100438 |
0.38 |
|
| 1997 |
Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis Cancer Immunology, Immunotherapy. 43: 355-360. PMID 9067407 DOI: 10.1007/S002620050344 |
0.452 |
|
| 1996 |
Magarian-Blander J, Hughey RP, Kinlough C, Poland PA, Finn OJ. Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells Glycoconjugate Journal. 13: 749-756. PMID 8910002 DOI: 10.1007/Bf00702339 |
0.383 |
|
| 1996 |
Finn OJ, Debruyne LA, Bishop DK. T cell receptor (TCR) repertoire in alloimmune responses. International Reviews of Immunology. 13: 187-207. PMID 8782741 DOI: 10.3109/08830189609061747 |
0.367 |
|
| 1996 |
Henderson RA, Finn OJ. Human tumor antigens are ready to fly. Advances in Immunology. 62: 217-56. PMID 8781270 DOI: 10.1016/S0065-2776(08)60431-9 |
0.468 |
|
| 1996 |
Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma Journal of Surgical Research. 63: 298-304. PMID 8667619 DOI: 10.1006/Jsre.1996.0264 |
0.425 |
|
| 1996 |
Pecher G, Finn OJ. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proceedings of the National Academy of Sciences of the United States of America. 93: 1699-704. PMID 8643693 DOI: 10.1073/PNAS.93.4.1699 |
0.389 |
|
| 1995 |
Fontenot JD, Mariappan SV, Catasti P, Domenech N, Finn OJ, Gupta G. Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. Journal of Biomolecular Structure & Dynamics. 13: 245-60. PMID 8579785 DOI: 10.1080/07391102.1995.10508837 |
0.365 |
|
| 1995 |
Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunological Reviews. 145: 61-89. PMID 7590831 DOI: 10.1111/J.1600-065X.1995.Tb00077.X |
0.489 |
|
| 1994 |
Finn OJ. Tumor-rejection antigens recognized by T lymphocytes. Current Opinion in Immunology. 5: 701-8. PMID 8240731 DOI: 10.1016/0952-7915(93)90124-B |
0.381 |
|
| 1994 |
Finn OJ. Tumor-specific immune responses and opportunities for tumor vaccines. Clinical Immunology and Immunopathology. 71: 260-2. PMID 8200128 DOI: 10.1006/Clin.1994.1083 |
0.432 |
|
| 1993 |
Magarian-Blander J, Domenech N, Finn OJ. Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Annals of the New York Academy of Sciences. 690: 231-43. PMID 7690213 DOI: 10.1111/J.1749-6632.1993.Tb44012.X |
0.451 |
|
| 1993 |
Bu D, Domenech N, Lewis J, Taylor-Papadimitriou J, Finn OJ. Recombinant Vaccinia Mucin Vector Journal of Immunotherapy. 14: 127-135. DOI: 10.1097/00002371-199308000-00008 |
0.396 |
|
| 1992 |
Finn OJ. Antigen-specific, MHC-unrestricted T cells. Biotherapy (Dordrecht, Netherlands). 4: 239-49. PMID 1377929 DOI: 10.1007/Bf02172653 |
0.368 |
|
| 1992 |
Kirk AD, Ibrahim MA, Bollinger RR, Dawson DV, Finn OJ. Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. Transplantation. 53: 329-38. PMID 1371194 DOI: 10.1097/00007890-199202010-00014 |
0.336 |
|
| 1992 |
Hand SL, Hall BL, Finn OJ. T cell receptor vβ Gene usage in hla-dr1-reactive human T cell populations the predominance of vβ8 Transplantation. 54: 357-367. PMID 1353916 DOI: 10.1097/00007890-199208000-00030 |
0.336 |
|
| 1992 |
Jerome KR, Bu D, Finn OJ. EXPRESSION OF TUMOR-ASSOCIATED EPITOPES BY EBV-IMMORTALIZED B CELLS AND BURKITTʼS LYMPHOMAS TRANSFECTED WITH EPITHELIAL MUCIN Journal of Immunotherapy. 11: 128. DOI: 10.1097/00002371-199202000-00027 |
0.364 |
|
| 1990 |
Lotze MT, Finn OJ. Recent advances in cellular immunology: implications for immunity to cancer. Immunology Today. 11: 190-3. PMID 2354026 DOI: 10.1016/0167-5699(90)90079-O |
0.42 |
|
| 1989 |
Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America. 86: 7159-63. PMID 2674949 DOI: 10.1073/Pnas.86.18.7159 |
0.45 |
|
| 1979 |
Ricciardi-Castagnoli P, Lieberman M, Finn O, Kaplan HS. T-cell lymphoma induction by radiation leukemia virus in athymic nude mice. The Journal of Experimental Medicine. 148: 1292-310. PMID 214507 DOI: 10.1084/Jem.148.5.1292 |
0.308 |
|
| 1979 |
Finn OJ, Boniver J, Kaplan HS. Induction, establishment in vitro, and characterization of functional, antigen-specific, carrier-primed murine T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 76: 4033-7. PMID 91171 DOI: 10.1073/Pnas.76.8.4033 |
0.376 |
|
| Show low-probability matches. |